CHRNA7 and schizophrenia: Together, these findings suggest that the failure of α7 nAChR ligands in clinical trials of their efficacy in patients with cognitive deficits, schizophrenia, and other CNS disorders may be ascribed in part to decreased expression of functional α7 nAChRs.